The Republican party yesterday took a major step towards their long-promised goal of repealing Obamacare – but it’s far from clear if they can agree on what should replace it.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh